Incorporating Immunotherapeutic Advances Into the Clinic: A Case Study in the First-Line Treatment of Metastatic Urothelial Cancer
More than 90% of bladder cancers are classified as urothelial carcinoma (UC).(1) With combination chemotherapy, advanced UC is associated with a median survival of approximately ___ months.(2)
B.) 15. Advanced UC has an estimated median survival of 15 months. Click the “Continue” button to learn more about immunotherapeutic advances in bladder cancer management.
1. NCCN. www.nccnorg/professionals/physician_gls/pdf/bladder.pdf.
2. von der Maase H, et al. J Clin Oncol. 2000;18:3068-77.
Daniel Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Co-Director, Signal Transduction Research Program
Yale School of Medicine
New Haven, CT
Stephanie Larson, PhD
Clinical Content Manager
Lisa R. Rinehart, MS, ELS
Director, Editorial Services
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI
Upon completion, participants should be able to:
- Use PD-L1 expression biomarker testing when appropriate in patients with treatment-naïve advanced or metastatic UC to help inform decisions associated with immune checkpoint inhibitors
This activity is intended for oncologists.
Statement of Need
The management of locally advanced or metastatic urothelial carcinoma (UC) has transformed significantly over the past 2 years with the emergence of immune checkpoint inhibitors. The rapidly changing landscape of immunotherapy in the treatment of UC and the use of PD-L1 testing to inform immunotherapy-related decisions highlights the need for oncologists to stay abreast of recently approved immunotherapies to appropriately incorporate these advances into their own clinical practice.
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medium/Method of Participation
This CME activity consists of a 0.25-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: April 19, 2019
Expiration Date: April 18, 2020
Estimated Time to Complete This Activity: 15 minutes
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Daniel Petrylak, MD
Consulting fees/advisory boards: Advanced Accelerator Applications, Amgen, Astellas Pharma US, Inc., AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Clovis Oncology, Eli Lilly and Company, Exelixis, Inc., F. Hoffman-La Roche Ltd., Incyte Corporation, Janssen Pharmaceuticals, Inc., Pfizer, Inc., Pharmacyclics LLC, Seattle Genetics, UroGen Pharma, Ltd.
Contracted research: Advanced Accelerator Applications, Astellas Pharma US, Inc., AstraZeneca, Pharmaceuticals, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly and Company, Endocyte, F. Hoffman-La Roche Ltd., Genentech, Innocrine Pharmaceuticals, Inc., MedImmune, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Progenics Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc., Seattle Genetics
Ownership interest (stocks/stock options – excluding mutual funds): Bellicum Pharmaceuticals, Inc., Tyme Inc.
The peer reviewers and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email firstname.lastname@example.org.
Operating system - Med-IQ supports the following operating systems:
- Microsoft Windows supported by Microsoft
- Mac OS supported by Apple
Browsers - Med-IQ supports the current version of each browser listed below, plus two prior versions:
Microsoft Internet Explorer
- Microsoft Edge
Operating system - Med-IQ supports the current operating system, plus two prior releases:
- Android (eg, Samsung Galaxy)
- Apple (eg, iPhone/iPad)
Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
- Android (Chrome)
- Apple (Safari)
Applications & Software
PDF Viewer - Adobe Acrobat Reader or Adobe Reader
Adobe Flash Player - Med-IQ supports the current version, plus two prior versions
For technical assistance, please refer to our Support Manual.
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Genentech.
© 2019 Med-IQ, Inc.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.